Dry eye symptoms improved in patients treated with Aldeyra Pharmaceutical’s topical ophthalmic reproxalap more than in control patients, according to data released by the company.
The phase 2b randomized, vehicle-controlled, parallel-group, double-masked clinical trial assessed safety and efficacy of reproxalap for treatment of signs and symptoms of dry eye disease.
The study included 300 patients with dry eye disease randomized equally to receive 0.1% or 0.25% reproxalap or vehicle for 12 weeks.
Patients treated with 0.25% reproxalap experienced a statistically significant and clinically
Uncategorized